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As molecular analysis and computational techniques improved
during the 1980s, the chemical structures of many biological
molecules were accurately determined for the ﬁrst time. With
these advances came the prospect of rational drug design to
target speciﬁc sites, aimed at successful human treatment.
One such target was the neuraminidase (or sialidase) enzyme
of the inﬂuenza virus, which is essential for viral replication and
is largely conserved across inﬂuenza A and B strains. A number
of molecules blocking the action of neuraminidase were syn-
thesized and tested, the most active of which, zanamivir
(Relenza
w), became the ﬁrst commercially available neuramini-
dase inhibitor (NI) for the treatment and prophylaxis of inﬂuenza.
However, zanamivir could only be delivered by inhalation or intra-
venously (because of rapid deactivation in the gastrointestinal
tract); thus research continued to identify a related compound
that could be administered orally. The result was oseltamivir
(Tamiﬂu
w), which, after initial development by Gilead Sciences
in 1997, was brought to market by F. Hoffmann-La Roche in
late 1999. Oseltamivir was unique in that it was delivered
orally via a bioavailable prodrug that was converted in the liver
into the potent and selective NI, oseltamivir carboxylate. As high-
lighted by Brian E. Davies in the ﬁrst part of this Supplement, the
predictable and consistent pharmacokinetic proﬁle of the drug
and low level of signiﬁcant drug interactions observed in early
clinical studies suggested that a product had been created that
was practical to administer and usable by a broad spectrum of
patients.
In the Phase III trials that followed, oseltamivir was shown to
be an effective intervention for the symptomatic treatment and
prophylaxis of inﬂuenza A and B infections in children 1 year
and adults of all ages, as described by Regina Dutkowski in the
second part of this Supplement. Oseltamivir was also found to
be generally well tolerated by all patient groups, with a similar
overall adverse event proﬁle to placebo. Despite successful
licensure of the drug, the key limitation of the clinical trial
data was the somewhat modest reduction in the duration of
symptoms seen with all NIs and, initially, somewhat limited
data relating to ‘harder’ public health outcomes, such as
reductions in complications, hospitalizations and mortality.
These data have emerged more widely over the last decade
and, whilst still hotly debated in some circles,
1 the balance of
probability is, in my view, still in favour of NIs reducing hospital-
izations and mortality. Even small individual effects can have a
large impact when applied across whole populations, as elo-
quently pointed out by the late Geoffrey Rose,
2 and the current
H1N1 pandemic is certainly one situation where such potential
beneﬁts might be realized, as well as further data generated
that might settle the debate.
Despite the above ﬁndings, adoption of the drug into routine
clinical practice for seasonal inﬂuenza has been slow (except in
Japan); concerns about massive consumer demand have
proved unfounded, and organizations such as the National Insti-
tute for Health and Clinical Excellence (NICE) in the UK have
limited prescribing in some territories.
3 However, by far the
biggest issue has been the lack of awareness among physicians
and patients that inﬂuenza could be speciﬁcally treated, as well
as an over-riding (and largely misguided) opinion that inﬂuenza
was not sufﬁciently serious to warrant speciﬁc intervention. The
latter has been driven by unusually mild seasonal disease activity
since 1999–2000, and persistent under-ascertainment of inﬂu-
enza as a cause of hospital admission in adults and children.
4
Apathetic attitudes towards the use of oseltamivir were
radically altered by the re-emergence of highly pathogenic
avian inﬂuenza A (H5N1) in South-East Asia, which has caused
a substantial number of human infections and deaths since
2003, and provoked a serious global focus on pandemic
preparedness.
5 Experts generally agreed that H5N1 had (and
still has) the potential to pose a pandemic threat comparable
to that which swept the globe in 1918–19, causing an estimated
40 million deaths. Oseltamivir was shown to be active
against the H5N1 virus in animal models and, as reported by
James R. Smith in the third part of this Supplement, to improve
survival in human H5N1 cases, particularly when started early
in the course of illness. Thus, the stockpiling of oseltamivir
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ii3became central to the pandemic preparedness plans of many
countries.
As we now know, the pandemic virus that appeared in early
2009 originated not from birds but, most probably, from swine.
Pandemic (H1N1) 2009 inﬂuenza currently appears to cause
mild and uncomplicated illness in the majority of patients, but
may also lead to severe disease and death, both in patients
with and without underlying illnesses or medical conditions. In
the UK, it has been reported that pandemic inﬂuenza deaths
have been most numerous in people aged 25–44 years, and
almost one-ﬁfth did not have underlying conditions of any sort.
6
As described by David Reddy in the ﬁnal part of this Supplement,
the pandemic (H1N1) 2009 virus is largely susceptible to oselta-
mivir (although a small number of H275Y resistant mutations
have almost inevitably occurred), and early clinical data indicate
that oseltamivir is an effective treatment. A number of studies
arenowunderwaywhichmayhavetheabilitytodetermineifindi-
viduals infected with the pandemic virus who were treated early
with an NI were less likely to be admitted to hospital and suffer
severe outcomes. There is already at least some early suggestion
that this may be the case.
7,8
The WHO and other public health bodies recommend oselta-
mivir for the treatment of pandemic (H1N1) 2009 in patients
who have developed or are likely to develop severe disease.
Nevertheless, the transition from minimal to extensive oseltami-
vir use during the initial stages of the pandemic has not been
completely smooth. Broad prescribing of oseltamivir for sus-
pected pandemic (H1N1) 2009 infection in countries such as
the UK, where patients have hitherto been largely unfamiliar
with the drug, has led to media stories surrounding side effects
and resistance. It will therefore be important to educate both
healthcare providers and the general public on the best use of
oseltamivir as the pandemic unfolds. I hope that readers will
ﬁnd the content of this Supplement, which offers an engaging
and helpful perspective on ‘the story so far’, useful.
Nottingham, January 2010
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